SILO PHARMA, INC. Debt Conversion, Converted Instrument, Amount
SILO PHARMA, INC. (SILO) reported Debt Conversion, Converted Instrument, Amount of $253.00 thousand for the 12-month period ending 2019-12-31, per its 10-K/A filed 2021-05-17.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2021-05-17
- SILO PHARMA, INC. debt conversion, converted instrument, amount for fiscal 2019 was $253.00K.
| Period end | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|
| 2019-12-31 | $253.00K 10-K/A · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |